加载中
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
前收盘价
US$13.07
+US$0.47 · +3.73%
盘中时间采用ET。市场数据可能有所延迟。
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$13.07
52周区间
当前US$13.07
盘中时间采用ET。市场数据可能有所延迟。
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$13.07
52周区间
当前US$13.07
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6767.1万 USD | 5787.7万 USD | 3627.5万 USD | 5212.1万 USD | 3305.3万 USD |
| 销货成本 | 1592.3万 USD | 1028.5万 USD | 897.6万 USD | 757.2万 USD | 689.1万 USD |
| 毛利 | 5174.8万 USD | 4759.2万 USD | 2729.9万 USD | 4454.9万 USD | 2616.2万 USD |
| 研究与开发 | 3.89亿 USD | 4.66亿 USD | 4.35亿 USD | 4.2亿 USD | 2.3亿 USD |
| 销售、一般及管理费用 | 1.2亿 USD | 1.26亿 USD | 1.16亿 USD | 9030.6万 USD | 7109.6万 USD |
| 营业费用 | 4.93亿 USD | 5.82亿 USD | 5.43亿 USD | 5.03亿 USD | 2.94亿 USD |
| 利息收入 | 2919.5万 USD | 4780.7万 USD | 4983.2万 USD | 854.2万 USD | 128.3万 USD |
| 折旧和摊销 | 1592.3万 USD | 1028.5万 USD | 897.6万 USD | 757.2万 USD | 689.1万 USD |
| 营业利润 | −4.41亿 USD | −5.34亿 USD | −5.15亿 USD | −4.58亿 USD | −2.68亿 USD |
| 净利润 | −4.13亿 USD | −5.19亿 USD | −4.81亿 USD | −4.74亿 USD | −2.68亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK1.42亿2.06%55.62亿 USD0.75%US$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI5473.79万0.55%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI5473.77万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM4566.77万0.06%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3969.03万0.02%1853亿 USD0.03%US$289.48+0.64%
ARK Genomic Revolution ETFARKG3782.56万1.85%15.57亿 USD0.75%US$51.30+4.08%
Vanguard Morningstar Small-Cap Growth ETFVBK2273.43万0.05%447亿 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF2064.44万0.02%954亿 USD0.05%US$235+0.80%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
